Source: PharmaTimes

Eli Lilly: Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT

The primary endpoint of the study is a 50% reduction in monthly migraine headache days

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating


Read more